Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.

被引：2
|
作者：
O'Brien, Mary E. R.
Eberhardt, Wilfried Ernst Erich
Altorki, Nasser K.
Spigel, David R.
Crino, Lucio
Tsai, Chun-Ming
Cho, Eun Kyung
Kim, Joo-Hang
Szczesna, Aleksandra
Hoffman, Philip C.
Burghuber, Otto
Keshavjee, Shaf
Orlov, Sergey
Serwatowski, Piotr
Wang, Jiuzhou
Foley, Margaret A.
Horan, Julie D.
Park, Jung Wook
Shepherd, Frances A.
Kelly, Karen
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol,Ruhrlandklin, Essen, Germany
[3] New Presbyterian Hosp Weill Cornell Med Coll, New York, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Perugia, I-06100 Perugia, Italy
[6] Taipei Vet Gen Hosp, Dept Chest Med, Div Thorac Oncol, Taipei, Taiwan
[7] Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan
[8] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[9] Yonsei Univ Heath Syst, Yonsei Canc Ctr, Seoul, South Korea
[10] Mazowieckie Ctr Leczenia Chorob Pluc, Otwock, Poland
[11] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[12] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[13] Univ Hlth Network, Princess Margaret Canc Ctr, Div Thorac Surg, Toronto, ON, Canada
[14] St Petersburg Med Univ, St Petersburg, Russia
[15] Specjalisty Szpital, Szczecin, Poland
[16] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[17] Novella Clin, Boulder, CO USA
[18] Astellas Pharma Global Dev, Northbrook, IL USA
[19] Princess Margaret Canc Ctr, Toronto, ON, Canada
[20] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7535
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
    Reguart, N.
    Cardona, A. F.
    Isla, D.
    Cardenal, F.
    Palmero, R.
    Carrasco-Chaumel, E.
    Rolfo, C.
    Massuti, B.
    Moran, T.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer
    Hess, Lisa M.
    Louder, Anthony
    Winfree, Katherine
    Zhu, Yajun E.
    Oton, Ana B.
    Nair, Radhika
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (06): : 643 - 652
  • [33] Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried E. E.
    O'Brien, Mary E. R.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Hoffman, Philip C.
    Orlov, Sergey V.
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4007 - +
  • [34] GLOBAL EFFICACY AND SAFETY RESULTS FROM THE TRUST STUDY OF ERLOTINIB MONOTHERAPY IN > 7000 PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    Mali, P.
    Arrieta, O.
    Gottfried, M.
    Van Meerbeeck, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 100 - 100
  • [35] Phase I study of polyphenon E (P) in addition to erlotinib (E) in advanced non-small cell lung cancer (NSCLC)
    Illum, H. B.
    Jafri, S. H. R.
    Mclarty, J.
    Mills, G. M.
    Dowell, J.
    Sharma, A.
    Wang, D. H.
    Nordberg, M. Lowery
    Cardelli, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    Hensing, T. A.
    Fidler, M. J.
    Wong, F.
    Polish, A.
    Watkin, W.
    Basu, S.
    Kaiser-Walters, K. A.
    Pool, M.
    Coon, J.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Merimsky, O.
    Cheng, C.
    Reck, M.
    Au, S.
    von Pawel, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
    Bazhenova, Lyudmila
    Gettinger, Scott N.
    Langer, Corey J.
    Salgia, Ravi
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Haney, Jeff
    Rivera, Victor M.
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Population-based evaluation of second-line palliative chemotherapy (SCT) versus erlotinib (E) in advanced non-small cell lung cancer (NSCLC) patients (pts).
    Noonan, Krista
    Ho, Cheryl
    Sun, Sophie
    Melosky, Barbara L.
    Laskin, Janessa J.
    Murray, Nevin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts).
    Dziadziuszko, R
    Wegrzynowicz, E
    Kardas, I
    Limon, J
    Jassem, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 695S - 695S
12345